Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) ...
Arvinas (NASDAQ:ARVN) continues to gain attention in Nasdaq Futures, advancing in targeted protein degradation therapies for ...
Q4 2025 earnings call recap: pipeline milestones, PROTAC FDA/PDUFA timeline, 2026 data catalysts, and cash runway—read now.
NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Administration (FDA) has ...
Arvinas (NASDAQ:ARVN) gains attention within the nasdaq composite for its targeted protein degradation approach and institutional support.
Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 “Today’s announcement further supports our goal to bring vepdegestrant to ...
AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results